Tern Plc convertible loan note extended

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (“IoT”) technology businesses, has announced that the maturity date of the Device Authority Limited Convertible Notes, as announced on 28 October 2022, has been extended to 31 December 2023 from 30 June 2023. Tern currently owns 53.8% of the Device Authority equity.

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcement made by the Company at 7.45 a.m. on 28 October 2022.

Tern plc is using its experience in pioneering leading-edge tech combined with a deep reach into expanding world markets to unlock the potential of UK companies who may be starting local, but are dreaming global.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

A new frontier for medical device trust and patient safety

Connected medical device risk is rising and a platform that automates identity, credential and data‑protection lifecycles may become an infrastructure segment worth watching.

When HCP Dialogue Becomes Quantifiable Intelligence

Talking Medicines’ DrugVoice platform turns real‑world HCP dialogue into measurable insight, letting brand‑teams forecast message resonance before launch.

Immersive cardiac training tech gaining ground in high-stakes procedures

Immersive simulation platforms like Fundamental XR are shaping the infrastructure behind safer, faster adoption of intracardiac procedures.

Search

Search